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Abstract 
 
Objective: There is no questionnaire to specifically monitor perceived adverse events of 
methylphenidate (MPH) on cognition, motivation and mood. The current study therefore had 
two goals. First, to harvest accounts of such putative events from transcripts of interviews in 
samples enriched for such potential experiences. Second, to use the derived data to generate 
items for a new questionnaire that can be used for monitoring such events in medication trials 
or routine clinical care.  
Method: Following a literature search aimed at identifying associations between MPH and 
cognition and/or motivation, a qualitative semi-structured interview was designed to focus 
specifically on the domains of cognition (i.e. reasoning; depth/breadth of thinking; 
intellectual capacity; creativity) and motivation (i.e. drive, effort; attitudes towards 
rewards/incentives). Interviews were conducted with 45 participants drawn from four groups; 
(a) Clinicians; child and adolescent psychiatrists and paediatricians specialising in ADHD 
(n=15);  (2) Teachers, with experience of teaching at least 10 medicated children with ADHD 
(n=10); (3) Parents of children with ADHD (n=8) treated with MPH; and (4) 
adolescents/adults with ADHD (n = 12). Purposeful sampling was used to selectively recruit 
ADHD participants whose histories suggested a degree of vulnerability to MPH adverse 
events. Data were analysed using a deductive approach to content analysis.  
Results: While we probed purposefully for cognitive and motivational adverse events, a third 
domain, related to mood, emerged from the reports. Therefore 3 domains, each with a number 
of sub-domains, were identified from the interview accounts: (i) Cognition (six subdomains; 
attention/concentration, changes in thinking, reduced creativity, sensory overload, memory, 
slower processing speed); (ii) Motivation (four subdomains; loss of intrinsic motivation for 
goal directed activities, external locus of control, lack of effort/engagement in daily tasks, 
increased focus on incentives); and (iii) Mood (three subdomains; dampening of 
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spontaneity/flat affect, mood dysregulation, increased anxiety/edginess). On the basis of these 
reports, 34 items were specified and incorporated into a prototype questionnaire which was 
piloted and refined on the basis of field-testing.  
Conclusions: Items were identified that capture potential/perceived cognitive, motivational 
and mood-related adverse events of MPH. The items generated will allow us to further 
develop and psychometrically examine their prevalence, and the extent to which they are 
associated with medication adherence, treatment outcome, impairment and other reported 
adverse events (e.g., loss of appetite/cardiovascular effects).  
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Introduction 
Methylphenidate (MPH), along with other stimulant and non-stimulant medications, is 
recommended for the treatment of attention deficit/hyperactivity disorder (ADHD) based on 
evidence of efficacy from randomized controlled trials (Graham et al., 2011; NICE, 2008). 
While generally well tolerated (Faraone & Buitelaar, 2010), MPH has been associated with a 
range of adverse events/reactions over both the short and medium/long term (Cortese et al., 
2013). The most common of these include loss of appetite, restricted growth and weight 
suppression (Faraone, Biederman, Morley & Spencer, 2008), increases in blood pressure and 
heart rate (Hammerness, Perrin, Shelley-Abrahamson & Wilens, 2011; Graham & Coghill, 
2008), sleep disturbances (Schachter, Pham, King, Langford & Moher, 2001), and possible 
exacerbation of existing tics (Pringsheim & Steeves, 2011).   
Short-term positive effects of MPH on cognition and motivation are well documented in 
neuropsychological studies (Coghill et al., 2014; Volkow et al., 2004). Stimulant medication 
may improve some cognitive functions (attention) but there are also reports that it impairs 
others such as divergent thinking (Douglas, Barr, Desilets & Sherman, 1995) flexibility and 
planning (Advocat, 2010) or creativity (Farah, Haimm, Sankoorikal & Chatterjee, 2008), at 
least in some cases. In terms of adverse events, laboratory studies provide some evidence of 
cognitive rigidity (Solanto, 1984), reward desensitization (Andersen, Napierata, Brenhouse, 
& Sonntag, 2008), altered attribution style/sense of agency (Carlson, Pelham, Milich, & Hoza, 
1993) and/or impaired memory (Sprague & Sleator, 1977) with some of these cognitive 
changes being dose-dependent such that higher doses lead to more impairing adverse events. 
Consistent with this notion, there are also reports in the literature of higher doses of MPH 
being more effective for behavioural management but impacting negatively on executive 
attention control and working memory (Berridge et al., 2006). Thus, if clinicians and families 
prioritise behavioural targets in treatment goals, this may limit potential impact of MPH on 
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academic achievement more generally, given the lower doses required for cognitive 
enhancement (c.f.,  Hale et al., 2011). Finally, there have also been reports of adverse 
emotional events (e.g., Pelham & Hoza, 1996), which are known to play a role in both 
cognitive ability and motivational style.  
While there are some reports that adverse events of MPH may manifest as changes in 
cognition and motivation, these may not be mentioned or questioned in the course of routine 
clinical practice. Regulatory bodies like the European Medicines Agency (EMA, 2010) 
require the monitoring and collection of pharmacovigilance data, which involves the 
monitoring of medication effects after licensing for adverse effects not reported or found in 
clinical trials. These data are required to be collated for potential adverse effects/events 
during the clinical development of psychotropic compounds and via post-marketing 
surveillance for up to 2 years in adult and paediatric populations. However, it is not well 
understood how consistently cognitive adverse events are reported once the regulatory 
monitoring and reporting period for the medication has ended (post 2 years for ADHD 
medication) as it depends on clinicians and patients spontaneously identifying and reporting 
these as adverse events or side effects (e.g., through yellow card reporting in the UK – 
MHRA, 2015).  
While typical acute adverse effect scales for stimulant treatments, such as the Safety 
Monitoring Uniform Report Form (SMURF; Greenhill et al., 2004) or the Side Effects Scale 
(Barkley et al., 1990) collate information such as ‘stares a lot’, ‘talks less’, ‘prone to crying’, 
‘anxious’, or ‘sadness’, detailed standardized assessments of potential adverse events of MPH 
across broader psychological domains – for instance those relating to cognition, motivation, 
and mood- are still lacking. Nevertheless, this may be of particular importance as it has been 
suggested that cognitive, motivational and emotional adverse events are significant reasons 
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for lack of adherence with, or discontinuation of, long-term medication use, particularly 
during adolescence (Charach et al., 2004; 2008; Lindstrom, 1994). 
The lack of routine monitoring of cognitive and motivational adverse events in everyday 
clinical practice could be linked to a more general lack of systematic monitoring of treatment 
response as many clinicians still rely on spontaneous reporting of adverse events by patients 
and parents (Kovshoff et al. 2012). It is also likely due to the fact that, compared to other 
elements of the putative MPH adverse event or effect profile, the concept of cognitive or 
motivational adverse events remains both poorly defined and articulated with no standardised 
approach to reporting available. Other potential reasons for the lack of focus on cognitive and 
motivational adverse events include that (i) they may be more difficult to observe than typical 
adverse events; (ii) they might be experienced as subtle and/or vague signs that are difficult 
to describe and self-report, particularly by younger children; (iii) they may be rare; (iv) it may 
be difficult to establish a causal link (if one exists) between these adverse events and the 
medication, or to differentiate between concerns specific to MPH and core or secondary 
symptoms of the ADHD itself; or (v) the benefits of MPH experienced by the patient and 
families may outweigh any potential cognitive or motivational adverse events experienced 
and so these adverse events may not be seen as sufficiently significant to warrant reporting.   
The current paper represents the first stage in a project to investigate cognitive and 
motivational adverse events following stimulant medication use as part of the European 
Commission 7th Framework Programme for research; Attention Deficit/hyperactivity Drugs 
Use Chronic Effects (ADDUCE; www.adhd-adduce.org - Grant no 260576) (Inglis et al., 
submitted; Murray et al., 2013). Within this larger programme of research, one subproject 
involved the development of a questionnaire to systematically measure putative cognitive and 
motivational adverse events following MPH treatment. This will eventually allow us to 
estimate the prevalence of such effects in the general population of individuals treated with 
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MPH, explore the association with adherence and treatment outcome, and assess their impact 
on daily functioning.  
Aims and Objectives 
The goal of this study was to generate items that characterise potential adverse events that 
may be associated with MPH as perceived by the patient, family, clinicians or teachers that 
impact on cognition and/or motivation. Our aim was to elicit examples of potential adverse 
cognitive and motivational events that, at least to our participants, were believed to be 
associated with MPH treatment so that these accounts could provide candidate items for a 
questionnaire that could then be validated in a larger representative sample. We first aimed to 
collect multiple examples and experiences of cognitive and motivational adverse events, 
including the key stakeholder groups in ADHD management (i.e. children and adults with 
ADHD, parents of children with ADHD, teachers and clinicians). The views and experiences 
described were then transformed into items that could be used to elicit quantifiable responses 
on a questionnaire. The questionnaire was then piloted in a group of children with ADHD, 
and subsequently refined to ensure acceptability and accessibility of items and concepts.  
Method 
Participants 
The research protocol and all study documents received University of Southampton 
(ERGO Study ID 681; RGO Ref 8377) and NHS Research Ethics Committee (REC Study ID: 
11/SC/0541) approval. Within this protocol, all participants were provided with information 
sheets describing the aims and objectives of the study, given the opportunity to reflect and 
ask questions about participation, and signed consent or assent forms describing how their 
interview data would be used. They were also provided with debrief forms outlining how to 
withdraw from the study if desired, obtain a copy of the findings when the study was 
complete, and signposting to additional services if required.  
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To maximise the chances of identifying a range of potential cognitive and motivational 
experiences associated with MPH treatment, and to ensure that we were able to saturate our 
data, purposeful sampling of four independent groups of approximately 8-12 participants 
each, were recruited from within the South of England; experienced ADHD clinicians, adults 
and adolescents with ADHD who self-identified as having experienced unwanted adverse 
events when taking MPH, parents of children with ADHD who self-reported that their child 
experienced unwanted adverse events when taking MPH, and experienced teachers of 
medicated children with ADHD (e.g., from special needs classes, pupil referral units). Thus, 
all of the participants had personal or professional experience with and/or history of general 
MPH adverse events. The group of clinicians (n = 15; 9 females, 6 males) with professional 
experience of treating ADHD, consisted of 6 paediatricians, 7 child and adolescent 
psychiatrists and 2 senior nurse prescribers specialising in ADHD. They were included in the 
study if they had a minimum of 5 years experience of prescribing MPH to patients with 
ADHD and opportunities for the follow-up consultations where they would have had a 
chance to examine potential adverse effects. Mean length of experience of MPH prescribing 
was 12.0 years (SD=6.6). Individuals with ADHD (n = 12; 7 females, 4 males, 1 preferred 
not to disclose) included three adolescents (ages 12 to 17 years, mean age 14.6 years, SD = 
2.5) and nine adults who had undergone relatively extended treatment (i.e., more than 12 
months of consecutive use) with MPH and self-reported experiencing adverse events when 
taking the medication. For parents of patients/individuals with ADHD (n = 8; 7 females, 1 
male), inclusion criteria stipulated that they had a child who had experienced evident adverse 
events whilst taking MPH (either past or present; we included any form of event that was 
deemed unwanted or adverse in the eyes of patients or families). Teachers (n = 10; 6 females, 
4 males) who had significant experience of teaching MPH-treated children with ADHD (min. 
10 children) were also interviewed. They had a mean duration of 6.4 years (SD=3.9) working 
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with medicated children with ADHD. To ensure confidentiality, participants were ascribed 
unique anonymised identifiers. These consisted of a letter referring to the category to which 
they belonged (C=clinicians, P=parents; T=teachers; AC=individuals with ADHD) and a 
number (e.g., C1 for Clinician number 1). We recorded interviews and transcribed and coded 
them immediately after interviewing participants so that we were able to sample to saturation 
(i.e. the point at which no new codes were returned from the interview transcripts). 
Interview Procedure 
The semi-structured interview was developed by the research team to include open-ended 
questions about potential cognitive and motivational adverse events perceived to be directly 
related to MPH (e.g., could you describe any positive/negative effect of MPH on your 
thinking).  After piloting the original interview schedule with three participants including one 
medicated adult with ADHD, one clinician, and one parent of an adolescent with ADHD, the 
final interview schedule comprised of a total of 34 questions focusing on cognitive (n=17) 
and motivational (n=17) adverse events.  Interviewers encouraged participants to describe 
any potential adverse events in their own words. When describing an experience, interviewers 
took care to clarify whether the participant believed the experience only appeared after or 
worsened since starting MPH. The participants were informed that the study was exploratory 
and that the aim was to shed light on any cognitive and/or motivational adverse events which 
they may have noticed in their professional practice and/or personal experience of MPH. 
Interviews were conducted by post-doctoral level researchers who had been trained to 
conduct qualitative interviews and had extensive experience in this technique. Interviews 
typically lasted for 60 minutes and occurred at a time and place that was convenient for 
participants (e.g. home, place of work or via telephone).  
Data Analysis 
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A content analysis approach to the data (Ritchie and Spencer, 1993) was employed as it 
provides a flexible and deductive method for analysing text data. For the current study, 
conventional content analysis was employed whereby coding categories were derived directly 
from the text (Hsieh & Shannon, 2005). While our interview was designed to gather 
information about positive and negative effects of MPH, given our overall aim was to 
develop a questionnaire measure of adverse events, only negative/adverse experiences/events 
of MPH treatment were coded. 
In the first phase, two researchers familiarised themselves with the transcripts through 
a thorough reading from beginning to end. Then, the researcher who performed the main 
analysis read each transcript carefully again, making notes and highlighting text that 
described the adverse events of medication in the pre-determined areas of cognition and 
motivation (e.g., memory, attention, creativity, etc.). The researcher then generated 
preliminary codes from the first five transcripts from each participant group, and coded the 
remaining transcripts using these original codes, adding new codes whenever new 
information was encountered that did not fit in with the existing codes. Whilst coding, the 
researcher collapsed or combined lower-level codes to form higher-level codes (for instance, 
‘inability to take in others’ point of view’ and ‘fixation on thoughts/actions’ were combined 
into higher-level code ‘rigidity of thought’, which then formed part of  ‘top-level’ code 
‘Changes in thinking’). During this process, a complete detailed coding manual devised by 
the first coder was scrutinised by the second. The second researcher independently re-coded 
10% of the transcripts, effectively re-testing all of the codes. Any differences between the 
codings were discussed until a mutual agreement on the final coding manual was achieved.  
 
Results 
Domains, Themes, and Subthemes 
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Overall, at least one cognitive and/or motivational adverse experience of MPH was 
reported by 89% of participants interviewed in this study (note that this figure does not relate 
to prevalence rates of adverse events in the general ADHD population treated with stimulants  
but only in our highly selective purposeful sample). Table 1 provides a summary of themes 
and subthemes by domain listed in order of frequency of report/nomination by participants 
(in descending order from the most commonly identified adverse experience/event with the 
medication), alongside a prototypical statement and illustrative quote for each. 
During the analysis stage, a third category of ‘mood’-related adverse events was 
added although it was not specifically probed in the study. A total of 84% of participants 
described cognitive; 80% mood-related, and 51% motivational adverse events. A detailed 
breakdown of these figures by domain and participant group is shown in Table 1. Table 2 
represents a summary of domains and sub-domains.  
____________________________________ 
Table 1 and 2 about here 
____________________________________ 
Cognitive. Cognitive AEs were most commonly reported. Six domains emerged, 
ordered according to frequency; (1) Poorer Attention/Concentration, (2) Changes in Thinking, 
(3) Reduced Creativity, (4) Sensory Overload, (5) Poorer Memory, and (6) Slower 
Processing Speed. (1) Negative events on Attention/Concentration were most commonly 
cited and divided into three subdomains; (i) ‘zoning out/staring’ leading patients to 
experience a lack of clarity of thought and tendency to stare into space for long periods of 
time, (ii)‘hyper- or over-focusing’ particularly leading to difficulties transitioning or dividing 
attention between tasks, and (iii) ‘increased distractibility’. (2) Undesirable Changes in 
Thinking patterns were the second most frequently mentioned domain of cognitive adverse 
events with MPH treatment, and it included two subdomains; (i)‘increased fixation on one’s 
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thoughts which included the single-minded absorption in one’s thoughts and/or preoccupation 
with doing things in a certain predetermined way and (ii) ‘rigid thinking’ led users to struggle 
to consider another’s point of view, or alternative ways of doing things.  
(3) Reduced Creativity was reported by individuals who described a sensation of 
overly structured thinking experienced at the expense of creativity. (4) The fourth cognitive 
domain involved Sensory Overload. Here, respondents reported that their senses were 
heightened often to an undesirable degree after taking MPH. This led to a hyper-awareness of 
surroundings which was perceived as negative and ultimately impacted on thinking, when 
experienced acutely. (5) Poorer Memory was reported by 18% of participants. In particular, 
individuals described increased forgetfulness and trouble remembering or recalling recent 
events. (6) The sixth and final cognitive domain mentioned was Slower Processing Speed; 
some participants talked about responding to events more slowly which led to a dampening of 
their competitive drive, while others spoke of slower thoughts which were particularly 
problematic for those who wished to be creative. Here, analytic depth was perceived to lead 
to the negative sensation of a reduction in quick thinking and an increase in the time it takes 
to process information.  
Motivation. The motivation category had four domains. (1) Firstly, 
experiences/events related to Loss of Intrinsic Motivation for Goal-Directed Activities 
referred to patients taking MPH who described themselves as more compliant and more able 
to complete activities, but experiencing less intrinsic motivation. (2) The second domain in 
relation to motivation was the development of an External Locus of Control. Participants 
reported that some individuals with ADHD may attribute behaviour regulation to medication 
rather than to their own ability. (3) Some individuals reported MPH led to a Lack of 
Effort/Engagement with Tasks, e.g., MPH was perceived to lead to increased difficulties 
initiating or participating in everyday tasks such as tidying or homework. (4) Finally, some 
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participants noted that MPH users were more demanding of and required Increased Focus on 
Rewards/Incentives to complete tasks on medication. They also reported that medication led 
to a greater expectation and need for others to praise or reward them for activities.  
Mood. A third domain, described as mood-related, emerged as the second most 
frequently cited adverse event of MPH. There were three sub-domains. (1) The most 
commonly cited being Dampening of Spontaneity. This included descriptions of individuals 
‘losing their spark’ and becoming ‘dull’ or ‘boring’ when medicated.  (2) The second most 
frequently described mood-related adverse event was related to Mood Dysregulation. Mood 
swings, emotional lability, and feelings of depression were reported.  Secondary 
repercussions of this involved individuals being unable to think about and focus on tasks 
given their experience of negative affect.  (3) Events related to Increased Anxiety whilst on 
medication were also mentioned. Here, participants gave the example of subjects choosing 
not to take MPH on days likely to be stressful (e.g., test days or important meetings) as they 
felt it would amplify and worsen anxiety.  
 
 
____________________________________ 
Table 3 about here 
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Initial Development of the Prototype Medication and Cognition 
Questionnaire. All of the domains and subdomains described in the coding manual 
and listed in Table 4 were used to develop prototypical questionnaire items for the 
Medication and Cognition Questionnaire (MCQ). Two items per domain/subdomain 
were created. Where possible, these were para-phrased from participants’ own words 
(See Table 3).  
The first draft of the questionnaire was piloted with 20 children with ADHD 
aged 7 – 16 years (Mean = 11.2; SD = 2.69) participating in the ADDUCE project 
(www.adhd-adduce.org) who had been taking MPH for 18 months.  Following this 
pilot phase, it was found that 20/34 items were not consistently understood by some 
of the younger participants. A focus group of six typically developing children aged 7 
who did not have diagnoses of ADHD was formed to help generate age-appropriate 
phrasing for these items. For example, the item ‘Had difficulty considering alternative 
ways of doing things was changed to ‘had trouble thinking of different ways to do 
things  (like when doing a maths problem)’. The final item set is listed in Table 4.  
The final questionnaire is being piloted within the larger ADDUCE project 
trial at the 18 month data collection point across the four European sites (UK, 
Hungary, Italy and Germany). These data will then be used to investigate the internal 
consistency and factor loading of the items, and to further refine the items as 
necessary, for example, to ensure they are developmentally appropriate, and 
understandable across a wide age range. We will also assess the psychometric 
properties of the MCQ, including conducting test-retest reliability with a subset of 
participants, and through tests of concurrent (e.g., looking at the relationship with 
mood measures) and predictive validity (looking at outcomes and medication 
adherence across the sample).  
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Discussion 
 Our interviews with our purposively selected and non-representative sample of 
clinicians, teachers, parents, and individuals with ADHD about their negative 
experiences and reports of MPH use, provided descriptions of potential adverse events 
of MPH on cognition, motivation, and mood, at least in most cases. The purpose of 
our qualitative interview was to harvest an in-depth and broad account of any 
potential cognitive or functional impact (regardless of dose), in a sample of 
participants enriched for experience/knowledge of adverse events/reactions to MPH. 
That is to say, participants all had direct (as in the case of patients) or indirect 
experience of adverse events/reactions more generally. Crucially, this was not a 
survey of adverse events associated with MPH in a representative sample of MPH-
treated ADHD patients, and so proportions of individuals reporting events cannot in 
any way be equated with prevalence rates, e.g., from controlled clinical trials or post-
market reporting. Determination of prevalence rates of these adverse events is 
currently being undertaken with the Medication and Cognition Questionnaire (MCQ) 
as part of the ADDUCE 2 year longitudinal naturalistic prospective 
pharmacovigilance study (Inglis et al., submitted) and will be reported separately.  
With these caveats in mind, our findings corroborate and extend the 
conclusions of an emergent body of literature that has sought to examine possible 
adverse impacts of stimulant medication from patient and practitioner perspectives. 
Accordingly, Charach, Yeung, Volpe, Goodale and DosReis (2014) conducted 
qualitative interviews with 12 young people aged 12 to 15 years and their parents to 
investigate their attitudes towards use of stimulant medication. While most 
participants noted benefits of stimulants in multiple domains, they also expressed 
concerns about negative changes in their subjective experience and feelings about 
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themselves. They reported that their medication caused them to feel less happy, 
quieter, ‘weird’, unsociable and less outgoing. They also noted other adverse events 
including headaches and mood lability, which alongside the undesirable changes in 
their sense of self, led to a desire to discontinue medication.  
Similarly, Meaux, Hester, Smith and Shoptaw (2006) interviewed 15 college 
students with ADHD about their experience of stimulant medication. While all 
participants agreed that stimulants improved their concentration and focus, many also 
recounted that taking stimulants involved a trade-off between any benefits of the 
medication and undesirable cognitive, behavioural, social, and physiological effects of 
the drug. In particular, they described feeling like everything was in slow motion, that 
their daily experiences involved feeling flat or ‘monotone’, and that the medication 
made them feel unsociable and “killed their personality” (p. 220). 
As part of the ADHD VOICES Study, Singh et al., (2010) conducted focus 
groups and 1:1 interviews with 16 young people with ADHD on medication to gather 
information about their experiences of stimulant treatment. Generally, the participants 
in their study did not report any specific adverse events of stimulant medication. 
However in their final report of this study, Singh (2012) acknowledges that a “small 
group of children” (p. 24) felt that stimulant medication “gave them a ‘second 
personality” (p. 24).  
When taking into account the perspectives of not only patients with ADHD 
but also parents, experienced clinicians, and teachers, the participants in our study 
identified adverse events that they perceived to be associated with MPH treatment and 
related to or associated with cognition, motivational style, and mood. Interestingly, 
participants in the current study also reported that individuals with MPH treatment 
developed strategies to manage any unwanted effects of the medication. For example, 
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those who believed that MPH exacerbated their anxiety would avoid taking their 
medication on days in which they were worried the impact of the medication might 
impede performance. However, failure to take prescribed medication may have other 
important costs to the individual where enhanced attention and concentration is 
required. Others were able to manage their medication use so that they chose when 
was most suitable for them to take their medication. For example, those who were 
required to be risk-taking or creative as part of their jobs or sporting activities avoided 
taking the medication for key events, and took it only when they felt it would be 
desirable to slow down thinking, and some of our participants only took it for tasks 
where creativity was not required. Still others expressed uncertainty about whether the 
adverse events they experienced could be directly attributed to the medication or to 
other causes such as puberty or co-morbid mental illnesses, or simply to a greater 
understanding or awareness of their ADHD symptoms. Management and 
identification of these sorts of adverse events require further attention and a more 
systematic and standardised approach to disentangle some of the issues raised.  
Moreover, further systematic study of these possible adverse events is also important 
in order to clarify their relationship with predictive/moderating variables (e.g., 
comorbid conditions, personality traits, genetic variance and potential relationships 
with physiological side effects). It would also be of clinical importance to identify 
which children are most likely to develop adverse cognitive, motivational or mood-
related adverse events (e.g., with co-occurring anxiety symptoms, for example).  
Limitations 
 While the participants in this study have introduced several interesting 
avenues for future research and consideration, it is important to note the caveats with 
which these data must be interpreted. This research represents a specific and goal-
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oriented exercise in gathering examples of adverse events associated with MPH 
treatment. For this purpose, a comparison group of individuals who did not experience 
negative effects of MPH were not required as the ultimate goal was to collate only the 
adverse events described during our interview study to develop a measure of adverse 
events related to/associated with MPH. This measure will now require testing in  large, 
representative samples of ADHD patients both on and off MPH medication, with and 
without a positive adverse effect profile, to control for bias effects. Additional testing 
and refinement may also be required to ensure that the measure has good validity and 
developmental sensitivity for both younger children and adult populations. Without 
this test of the data, the adverse events reported here cannot and should not be directly 
attributed to MPH.  
Implications 
The limitations above notwithstanding, our tentative findings extend some of 
the recent reports of adverse events of MPH in the literature by specifically 
addressing the putative negative impact of MPH treatment on the specific domains of 
cognitive, motivational and mood functioning with a broader range of participant 
groups. Despite the more common experience of positive effects of MPH therapy, for 
some individuals at least, the perceived negative impact of MPH use on their thinking, 
mood, and motivation has potential implications for treatment. Many clinicians 
interviewed in this study noted that they did not routinely screen for these types of 
adverse events and only recorded them if the patient spontaneously reported them. 
Accordingly, the use of a standardised tool to gather information about cognitive, 
motivational and mood effects of MPH in clinical practice may help to focus psycho-
educational approaches on respective findings, and thus, hopefully contribute to 
medication adherence and treatment alliance (Adler & Nierenberg, 2010). Moreover, 
21 
 
a greater understanding of the potential adverse events of medication on these 
important, but often overlooked areas, will ultimately improve individualized patient 
care.   
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